bioRxiv Science⌕ Search

Biology subjects

Mathieu, T.

Publications and source records attributed to Mathieu, T..

2 recordsLinked to original sources

Integrative multi-omics modelling for cultivated meat production, quality, and safety

Cell culture technology, which offers a promising solution for complementary food production, is slowly becoming a reality with the first wave of regulatory approvals in pioneering markets. However, significant challenges remain for large-scale cultivated meat commercialization, including effective scaling, cost efficiency, and product quality, but also scientific evidence to support regulatory approval and building consumer trust. In this paper, we discuss the potential of an integrative multi-omics approach to characterize and optimize cultivated meat production. By analyzing a network-based interactome model that integrates the transcriptomic, proteomic, and metabolomic layers, we achieve a system-level understanding of cellular metabolism and regulatory mechanisms. This approach can allow for precise monitoring and targeted interventions of critical quality and safety attributes associated with cellular biomass. We then describe a Target-Action-Metabolite (TAM) framework, which utilizes insights from the interactome to optimize cell culture conditions through actionable interventions. We illustrate the potential use of this framework through a case study involving Duck Embryonic Stem Cells (dESCs) for use in cell-cultured meat products, providing hypotheses for improving key metabolic pathways through targeted interventions on metabolites present in culture media. Finally, our paper highlights the potential of this interactome-based strategy to enhance bioprocess efficiency, improve product quality and ensure safety attributes, addressing regulatory challenges associated with cultivated meat production. HighlightsO_LIIntegrative multi-omics as a novel approach to support cultivated meat production. C_LIO_LIInteractome Models map molecular interactions to monitor and improve production. C_LIO_LIMulti-omics based strategy to scientifically support cell-culture safety assessment. C_LIO_LITarget-Action-Metabolites Framework to guide non-genetic interventions. C_LIO_LICase study with avian interactome model to enhance cellular metabolism. C_LI

bioinformatics↗

In vitro and in vivo Antiviral Activity of the Acyclic Nucleoside Phosphonate Prodrug LAVR-289 against Poxvirus and African Swine Fever Virus Replication

Poxviruses are double-stranded DNA viruses including relevant zoonotic pathogens with high morbidity. Although African swine fever virus (ASFV) belongs to the Asfarviridae family and is not strictly classified as a member of the Poxviridae, both fall within the same class of Pokkesviricetes that replicate in the cytoplasm, and some poxviruses pose potential biological warfare threats. Among compounds targeting these viruses, acyclic nucleoside phosphonate prodrugs are nucleoside analogues inhibitors of viral DNA polymerases that have been identified as promising agents. However, some limitations related to their toxicity and the rapid emergence of resistance highlight the need for new antiviral molecules. In this study, the new nucleoside analogue LAVR-289 was shown to effectively inhibit the viral replication by intervening early in the viral replication step, targeting a specific domain of the poxvirus DNA polymerase. Using monkeypox virus models, the subcutaneous or oral administration of LAVR-289 demonstrates protective efficacy in infected animal models without toxicity or behavioral modification. The stability in vivo, long shelf-life and efficacy make LAVR-289 a promising candidate for further development and stockpiling as a medical countermeasure against dsDNA virus outbreaks. Its broad-spectrum efficacy is a real asset in a context of recurrent viral epidemics, risk of bioterrorism and emergence of resistance strains in the population. HighlightsO_LILAVR-289 is a unique acyclic nucleoside phosphonate prodrug targeting viral DNA polymerases. C_LIO_LILAVR-289 displays antiviral activity against dsDNA viruses, ASFV and poxviruses. C_LIO_LIFirst report of in vivo evaluation of LAVR-289 against MPXV by subcutaneous and oral administration. C_LIO_LILAVR-289 reduces clinical signs and increase survival in animal models. C_LI

microbiology↗